MNV
Market News Video
MNV MNV 10 Oversold Stocks You Need To Know About
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Investors Snatch BTAI 10.0% Lower Than Its Secondary Stock Offering
Thursday, October 29, 1:22 PM ET, by Market News Video Staff

Looking back to 93 days ago, BioXcel Therapeutics Inc (BTAI) priced a 4,000,000 share secondary ...

Analysts Forecast 10% Gains Ahead For PBSM
Friday, November 13, 7:55 AM ET, by Market News Video Staff

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...

Interesting BTAI Put And Call Options For January 2021
Friday, November 20, 10:56 AM ET, by Market News Video Staff

Investors in BioXcel Therapeutics Inc (BTAI) saw new options begin trading this week, for the ...

Noteworthy Monday Option Activity: SKT, BTAI, PBYI
Monday, November 23, 3:19 PM ET, by Market News Video Staff

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume ...

LABU, BIIB, BTAI, BLUE: Large Outflows Detected at ETF
Tuesday, November 24, 10:57 AM ET, by Market News Video Staff

Symbols mentioned in this story: LABU, BIIB, BTAI, BLUE Exchange traded funds (ETFs) trade just ...

Investors Land BTAI Even Cheaper Than Its Secondary Stock Offering

By Market News Video Staff, Friday, June 25, 10:33 AM ET
Play Video: The Importance of ETFs


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Email EnvelopeFree Email Alerts By Stock:
Get Dividend Alerts
Get SEC Filing Alerts

Looking back to 2 days ago, BioXcel Therapeutics Inc (NASDAQ:BTAI) priced a 3,155,000 share secondary stock offering at $31.70 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time. In trading on Friday, bargain hunters could buy shares of BTAI and achieve a cost basis 1.7% cheaper than those buyers, with shares changing hands as low as $31.15 per share.

Secondaries can often present buying opportunities for bullish investors interested in purchasing shares, because the sudden extra supply of stock tends to require that the offering be priced at an attractive discount to where the stock had previously been trading before the offering announcement. At last check, BioXcel Therapeutics Inc shares are currently trading up about 1% on the day. The chart below shows the one year performance of BTAI shares, versus its 200 day moving average:

BioXcel Therapeutics Inc Chart

Looking at the chart above, BTAI's low point in its 52 week range is $28 per share, with $71.50 as the 52 week high point — that compares with a last trade of $31.33.


Special Offer: Receive our best dividend ideas directly to your inbox each afternoon with the Dividend Channel Premium Newsletter


This Article's Word Cloud:   BTAI   BioXcel   Buyers   Channel   Dividend   Friday   Looking   Newsletter   Offer   Offerings   Premium   Receive   Recent   Secondaries   Secondary   Special   Start   Stock   Therapeutics   about   above   achieve   afternoon   announcement   attractive   average   back   bargain   basis   because   been   before   below   best   bullish   buyers   buying   chart   investment   last   offering   point   priced   share   shares   stock   that   trading   week   with
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy
MNV
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Portfolio Channel Stock Market Definitions
MNV

Investors Land BTAI Even Cheaper Than Its Secondary Stock Offering | Market News Video | Copyright © 2008 - 2021, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.